Julio Duarte
University of Florida, FL·Pharmacology
The same medicine can work well for one person and fail or cause side effects in another, partly because of differences in genes. Pharmacogenetic (PGx) testing reads a patient's genes to guide drug choice and dose.
- Fields
Pharmacology
Medicine & Clinical Research
Public Health & Epidemiology
- Topics
pharmacogenetics
pharmacogenomics
PGx
- Grants
- 2 known grants, through Jan 2030
What they work on
- Expand pharmacogenetic prescribing decision support for emergency and post-emergency care to include drug–drug–gene interactions, more gene–drug pairs, pharmacist medication reviews and recommendations for prescribers outside the health system.
- Test whether pharmacogenetic testing reduces emergency department return visits and hospitalizations in high-risk frequent ED patients, using a randomized pragmatic clinical trial against usual care.
- Estimate the cost-effectiveness and net benefit of pharmacogenetic testing in the emergency department, using cost per averted return visit as the main outcome at different levels of revisit reduction.
- Identify clinical, demographic and socioeconomic factors tied to prescribing of drugs with pharmacogenetic guidelines, by linking prescription records from millions of Florida patients with patient data.
- Develop a low-cost, ancestrally comprehensive pharmacogenetic panel and test preemptive testing in underserved patients with a randomized open-label trial and patient and provider interviews.
More about the research
Little is known about how to bring this testing into routine care for the patients who might benefit most. The lab studies where PGx testing improves outcomes and lowers costs, focusing on emergency department patients and medically underserved populations.
Why it matters
Genetic testing to guide prescribing could reduce failed treatments and side effects, but it is rarely used in emergency care or among underserved patients. This work could show whether PGx testing cuts repeat ED visits and costs, and whether a low-cost, ancestrally inclusive panel can serve underserved communities. The findings may help hospitals decide when and how to adopt testing and reduce medication-related health disparities.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
Rachel Solnick
Icahn School of Medicine at Mount Sinai, NY·Medicine & Clinical Research·Early-career
Develop the TIPPED protocol, which uses routine post-discharge callbacks about STI results to offer HIV pre-exposure prophylaxis (PrEP), together with an implementation strategy shaped by stakeholder input.
Neha Goel
Icahn School of Medicine at Mount Sinai, NY·Medicine & Clinical Research·Early-career
Develop a practical protocol for using and managing high flow nasal oxygen (HFNO) for low-oxygen acute respiratory failure in the emergency department, using feedback from a national panel of experts and current evidence.
Folasade May
University of California-Los Angeles, CA·Medicine & Clinical Research
Compare a multilevel patient, provider and health-system intervention against usual care in a six-clinic cluster randomized trial, measuring colonoscopy completion within 6 months of an abnormal fecal immunochemical test (FIT) at an FQHC.
The school
University of Florida: 65 labs on PI Pages, $1.3B a year on research, 795 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.